logo

For the Inventor, By the Inventor

Tokyo, Japan

Kenichiro Kataoka

USPTO Granted Patents = 13

 

Average Co-Inventor Count = 7.5

ph-index = 7

Forward Citations = 163(Granted Patents)


Location History:

  • Hino, JP (1995 - 2009)
  • Tokyo, JP (1996 - 2010)

Company Filing History:

goldMedal8 out of 1,587 
 
Teijin Limited
 patents
silverMedal4 out of 125 
 
Teijin Pharma Limited
 patents
bronzeMedal1 out of 832,843 
Other
 patents

Years Active: 1995-2010

Loading Chart...
Loading Chart...
13 patents (USPTO):Explore Patents
1. 7667036 - Pyrazolo[1,5-a]pyrimidine derivatives (2010-02-23),
2. 7557110 - Pyrazolo[1,5-A] pyrimidine derivatives (2009-07-07),
3. 7528140 - Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors (2009-05-05),
4. 7473694 - Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof (2009-01-06),
5. 7417053 - Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof (2008-08-26),
6. 7396642 - Methods of screening for a compound that enhances thermogenesis (2008-07-08),
7. 6686353 - Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists (2004-02-03),
8. 5990346 - Prostaglandins and processes for production thereof (1999-11-23),
9. 5731452 - 7-thiaprostaglandins and method of production thereof (1998-03-24),
10. 5661148 - Pyrrolo[2,3-d]pyrimidine derivatives, process for producing the same and (1997-08-26),
11. 5574061 - Benzopyran derivative, process for producing the same and pharmaceutical (1996-11-12),
12. 5496853 - Benzoxa condensed ring compounds, process for producing the same and (1996-03-05),
13. 5378700 - Fused pyrimidine derivative, process for preparation of same and (1995-01-03),

Title: Kenichiro Kataoka: Innovator in Pharmaceutical Chemistry

Introduction

Kenichiro Kataoka is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative compounds with therapeutic potential. With a total of 13 patents to his name, Kataoka's work has the potential to impact various medical conditions.

Latest Patents

Kataoka's latest patents include the development of Pyrazolo[1,5-a]pyrimidine derivatives. These derivatives, represented by formula I, and their pharmaceutically acceptable salts exhibit excellent MAPKAP-K2 inhibiting activity. Drugs comprising these compounds are expected to be useful as therapeutic or prophylactic agents for MAPKAP-K2 mediated disorders, such as inflammatory diseases, autoimmune diseases, destructive bone disorders, cancer, and tumor growth. Additionally, he has developed another set of Pyrazolo[1,5-a]pyrimidine derivatives that demonstrate excellent kinase inhibiting activity. These drugs are anticipated to be effective in treating protein kinase mediated disorders, which include similar medical conditions.

Career Highlights

Throughout his career, Kenichiro Kataoka has worked with notable companies, including Teijin Limited and Teijin Pharma Limited. His expertise in pharmaceutical chemistry has allowed him to contribute to the development of innovative therapeutic agents.

Collaborations

Kataoka has collaborated with esteemed colleagues such as Tomomi Kosugi and Gen Unoki. These collaborations have further enhanced his research and development efforts in the pharmaceutical field.

Conclusion

Kenichiro Kataoka's contributions to pharmaceutical chemistry through his innovative patents and collaborations highlight his role as a significant inventor in the industry. His work continues to pave the way for advancements in therapeutic agents that can address critical medical challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…